Fintel reports that on October 30, 2024, EF Hutton initiated coverage of Carisma Therapeutics (NasdaqGM:CARM) with a Buy recommendation. As of October 22, 2024, the average one-year price target ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback